Medisch Centrum Leeuwarden B.V. — Clinical Trial Site

135 Registered trials

60 Currently recruiting

Organisation

Medisch Centrum Leeuwarden B.V.

Location

Leeuwarden, Netherlands

Identifier

ORG-100042953

Address

Thialfweg 44, 8441 PW, Netherlands

Departments

#2202; oncology
#2914:Cardiology
#3354:Cardiology
2609:Hart- en vaatcentrum
4903: Pulmonology
Afdeling Longziekten
Afdeling Reumatologie
Anesthesiologie
Cardiology
Department of Medical Oncology
Department of Surgery
Emergency Department
Frisius Medisch Centrum
Gynaecology
Hart- en Vaatcentrum
Hemato-oncology
Hematology
ICU
Intensive Care
Internal Medicine
Internal Oncology
interne geneeskunde
Interventional Cardiology
Kindergeneeskunde
Long
Longgeneeskunde
Medical oncology
Medische Oncologie
N/A
NA
Nephrology
Neurology
Obstetrics & Gynecology
OCL
Oncologie
Oncologisch Centrum
Oncologisch Centrum Leeuwarden
Oncologisch Centrum Leeuwarden (OCL) and Internal Medicine - Hematology
Oncology
Oncology center Leeuwarden
orthopedics
Polikliniek en Dagcentrum OCL
Pulmonary diseases
Pulmonary Science
Pulmonology
Rheumatology
Surgery
Urologie
Ward (Internal Medicine)

Clinical trials at this site (135)

Search interface

SAFEST Not authorised

2022-502059-79-00 Ischemic stroke or transient ischemic attack 6
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Sarilumab efficacy and safety in adults with early polymyalgia rheumatica Pending

2024-511296-15-00 Musculoskeletal diseases 5
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
REVITALISE Study Pending

2025-522060-32-00 STEMI (ST elevated Myocardial Infarction) 4
Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Triple negative breast cancer 5
Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD) Pending

2025-525068-13-00 Chronic Kidney Disease 4
A clinical trial of V940 with or without MK-3475A in people with non-small cell lung cancer (V940-014) Recruiting

2025-522643-18-00 Stage I NSCLC 5 2026-06-16
A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific… Recruiting

2025-522767-15-00 Acute Myeloid Leukemia 5 2026-01-27
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting

2024-517700-12-00 Rectal cancer 5 2025-12-10
ASPIRING Recruiting

2024-516188-10-00 Intracerebral haemorrhage 6 2025-10-07
A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C… Recruiting

2024-517968-36-00 non-small cell lung cancer 5 2025-07-08
A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML… Recruiting

2024-512733-32-00 Acute Myeloid Leukemia (AML) 5 2025-03-31
A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision fo… Recruiting

2024-517410-15-01 Rectal cancer 5 2025-01-14
A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI… Recruiting

2024-511404-17-00 Unresectable or metastatic NRAS mutant cutaneous melano 5 2024-10-07
Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study Recruiting

2024-510617-15-00 Non-metastatic resectable pancreatic cancer 5 2024-09-06
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
PUMP-IT RCT: Hepatic arterial infusion PUMP chemotherapy combined with systemic therapy versus systemic therapy alone as Induction Therapy f… Recruiting

2023-506194-35-00 Colorectal liver metastases 5 2026-05-22
Optimization of pain management for acute renal colic in the Emergency Department – The OPTIMIZED trial Recruiting

2025-521316-19-00 Urolithiasis 6 2026-04-20
Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait A… Recruiting

2025-523692-39-00 locally advanced rectal cancer 5 2026-03-11
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
Clinical Randomised Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation. Recruiting

2025-521377-14-00 Atrial fibrillation 4 2025-10-06